• image06

    The bottom Line is

    Excellence

  • image01

    The bottom Line is

    Depth

  • image02

    The bottom Line is

    Differentiation

  • image04

    The bottom Line is

    People

  • image03

    The bottom Line is

    Efficiency

  • image05

    The bottom Line is

    Happiness

Lupin Announces Strategic Alliance for Emerging Markets

Lupin Limited (Lupin) announced today that it has entered into a long-term strategic partnership with Merck Serono, the Biopharmaceutical division of Merck.

Lupin and Salix Announce Exclusive Distribution Agreement for Canada

Lupin Limited and Salix Pharma announced today that they have entered into a definitive distribution agreement under which Salix has granted Lupin exclusive rights to the market

Lupin launches Basugine™

Pharma Major, Lupin Limited (Lupin) today announced a strategic distribution agreement with LG Life Sciences (South Korea) to launch Insulin Glargine, a novel insulin analogue under the brand name Basugine™. According to the agreement, Lupin would be responsible for marketing and sales of Basugine™ in India.

Quarter I Results, FY 2014-15

Pharma Major, Lupin Ltd. reported its performance for the first quarter ending 30th June, 2014. These unaudited results were taken on record by the Board of Directors at a meeting in Mumbai today.

Lupin Receives the 2014 ASTD BEST Award for Learning & Development

Pharma Major Lupin Limited (Lupin) announced today that the company has received the prestigious American Society for Training and Development (ASTD) BEST Award for Learning & Development for the year 2014. The award recognizes organizations that leverage the learning function as a strategic business tool to get results and which create, support, and champion learning opportunities to drive performance and build a learning culture.

Lupin Launches Generic Cipro® for Oral Suspension in the US

Pharma Major Lupin Limited (Lupin) announced today that the company’s US subsidiary, Lupin Pharmaceuticals Inc. (LPI) has launched its Ciprofloxacin for Oral Suspension, 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL) in the US having received final approval from the FDA earlier.

Stock Price

FINANCIALS SNAPSHOT

Standing on the shoulders of sustained growth in the past, we have delivered the best growth numbers in the Industry for the last 6 years.

Read more
MEDIA CENTER

Lupin launches Generic Geodon® Capsules Receives final FDA Approval for its Generic Geodon® Capsules.

Read more
THE LUPIN STORY

The company was named after the Lupin flower because of the inherent qualities of the flower.

Read more

OUR GLOBAL WEBSITES

USA
Japan (Kyowa) JAPAN (I’rom)
South Africa
Australia
Philippines
Germany
NETHERLANDS
MEXICO